Novo to Debut Real-World Wegovy vs Resmetirom MASH Data at AASLD 2025
Novo Nordisk will unveil real-world PLATINUM-Truveta data comparing semaglutide 2.4 mg with resmetirom in MASH at AASLD 2025, with results still undisclosed.
Read article →Novo Nordisk will unveil real-world PLATINUM-Truveta data comparing semaglutide 2.4 mg with resmetirom in MASH at AASLD 2025, with results still undisclosed.
Read article →A 2026 records study finds fewer falls on semaglutide or tirzepatide in older adults with diabetes, while Wegovy's label flags more hip and pelvic fractures in patients 75…
Read article →